- Home
- HRMY vs QS Comparison
HRMY vs QS Comparison
Compare HRMY & QS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HRMY | QS |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.8B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HRMY | QS |
|---|---|---|
| Price | $38.04 | $4.03 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 9 |
| Target Price | ★ $48.25 | $5.79 |
| AVG Volume (30 Days) | 750.6K | ★ 11.5M |
| Earning Date | 11-03-2026 | 10-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.97 | ★ 19.15 |
| EPS | ★ 1.84 | N/A |
| Revenue | ★ $868,453,000.00 | N/A |
| Revenue This Year | $18.62 | N/A |
| Revenue Next Year | $13.23 | N/A |
| P/E Ratio | $20.62 | ★ N/A |
| Revenue Growth | ★ 21.51 | N/A |
| 52 Week Low | $25.81 | $3.80 |
| 52 Week High | $43.49 | $18.56 |
Technical Indicators
Market Signals| Indicator | HRMY | QS |
|---|---|---|
| Relative Strength Index (RSI) | 42.84 | 31.70 |
| Support Level | $37.48 | N/A |
| Resistance Level | $39.35 | $5.34 |
| Average True Range (ATR) | 1.28 | 0.21 |
| MACD | -0.24 | -0.03 |
| Stochastic Oscillator | 50.52 | 24.54 |
Price Performance
Historical ComparisonAbout HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About QS QuantumScape Corporation
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles and other applications. The company's solid-state lithium-metal battery technology is designed to offer greater energy density, faster charging, and enhanced safety. Its battery cells have none of the host materials used in conventional nodes. The company operates in one operating segment only.